Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the four research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $85.25.

Several equities research analysts have recently commented on PBH shares. DA Davidson reissued a "buy" rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. Finally, Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th.

Prestige Consumer Healthcare Trading Down 2.2 %

Shares of PBH stock traded down $1.72 during trading hours on Tuesday, hitting $76.70. 158,222 shares of the company were exchanged, compared to its average volume of 269,806. The company has a 50 day simple moving average of $79.79 and a two-hundred day simple moving average of $75.10. The firm has a market cap of $3.79 billion, a P/E ratio of 18.67, a P/E/G ratio of 2.21 and a beta of 0.51. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare has a fifty-two week low of $60.00 and a fifty-two week high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analysts' expectations of $282.09 million. During the same quarter last year, the firm posted $1.07 earnings per share. The company's revenue for the quarter was down .9% compared to the same quarter last year. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.46 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares of the company's stock, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the transaction, the senior vice president now owns 18,835 shares of the company's stock, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 in the last quarter. Insiders own 1.60% of the company's stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock valued at $19,630,000 after acquiring an additional 8,533 shares in the last quarter. Geode Capital Management LLC raised its holdings in Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock valued at $95,678,000 after buying an additional 50,961 shares during the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 12.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock worth $708,000 after acquiring an additional 1,120 shares in the last quarter. Barclays PLC lifted its holdings in shares of Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after purchasing an additional 71,730 shares during the last quarter. Finally, Avior Wealth Management LLC grew its position in Prestige Consumer Healthcare by 1,570.7% during the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock valued at $668,000 after purchasing an additional 8,042 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.